Published in Cancer Res on May 01, 2006
Immunomodulatory functions of type I interferons. Nat Rev Immunol (2012) 3.73
Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett (2014) 1.55
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol (2009) 1.43
Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther (2011) 1.10
Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors. Semin Cancer Biol (2007) 1.01
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients. Eur J Immunol (2012) 1.01
Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. J Transl Med (2007) 0.97
The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines. Clin Cancer Res (2009) 0.86
Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host. Biology (Basel) (2013) 0.86
An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer. Cancer Res (2012) 0.86
Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments. J Transl Med (2011) 0.85
Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression. Oncoimmunology (2014) 0.84
CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Cancer Immunol Immunother (2011) 0.84
Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology (2015) 0.83
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. Cancer Immunol Immunother (2013) 0.82
Tumor cell-derived microparticles: a new form of cancer vaccine. Oncoimmunology (2015) 0.76
Advances in cellular therapy for the treatment of thyroid cancer. J Oncol (2010) 0.76
A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas. Cancer Immunol Immunother (2016) 0.76
Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs. J Clin Pharmacol (2015) 0.76
Systematic evaluation of immune regulation and modulation. J Immunother Cancer (2017) 0.75
Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A (2007) 13.58
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol (2007) 6.68
New common variants affecting susceptibility to basal cell carcinoma. Nat Genet (2009) 4.15
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer (2007) 3.80
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta (2009) 3.28
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One (2009) 3.10
Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med (2002) 3.02
Interleukin-12: biological properties and clinical application. Clin Cancer Res (2007) 3.00
A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97
ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells. J Exp Med (2002) 2.92
Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res (2007) 2.80
Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res (2006) 2.77
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res (2006) 2.61
Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood (2002) 2.59
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 2.57
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol (2008) 2.33
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother (2004) 2.16
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol (2012) 2.03
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst (2004) 2.02
Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology (2005) 2.00
Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics (2005) 1.99
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother (2011) 1.94
Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res (2007) 1.86
Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev (2002) 1.84
IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol (2002) 1.82
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol (2006) 1.75
Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res (2010) 1.74
Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. J Immunol (2005) 1.71
Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage (2004) 1.67
Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev (2002) 1.66
Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol (2002) 1.63
Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol (2003) 1.61
Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer (2004) 1.61
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res (2003) 1.60
A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J Exp Med (2004) 1.59
5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J Natl Cancer Inst (2005) 1.59
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med (2014) 1.59
pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer (2010) 1.58
BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene (2004) 1.58
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst (2002) 1.56
Concomitant activation of Wnt pathway and loss of mismatch repair function in human melanoma. Genes Chromosomes Cancer (2008) 1.50
NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients. Clin Cancer Res (2007) 1.50
Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie (2007) 1.48
Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol (2009) 1.48
Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases. N Z Med J (2003) 1.47
Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol (2012) 1.46
Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res (2003) 1.46
Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol (2012) 1.45
Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. Int J Cancer (2012) 1.45
Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol (2004) 1.43
Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab (2013) 1.42
Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res (2012) 1.41